Habib Torfi's Email & Phone Number

💼 Past Experience

Habib Torfi is a chairperson, CEO and president at Invitrx, a technology company focused on the development of immunotherapy drugs. As CEO and president, he is responsible for the day-to-day operations of the company.Prior to joining Invitrx, Torfi was the CEO of the biotech company Myriad Genetics, where he led the company's operations until it was purchased by Myriad in 2011. From 1998 to 2001, Torfi served as the chairman of the board of directors of Akamai Technologies. From 1996 to 1998, he was CEO of John Brown & Sons, a plastics company.Torfi received his B.S. in 1968 from Brown University and his M.B.A. in 1974 from Myriad Genetics.

💡 Technical & Interpersonal Skills

Habib Torfi commenced his career as a research chemist in 1990 at the University of Alberta, where he obtained his doctorate in biochemistry. From 1991 to 1992, he worked as a postdoctoral researcher at Boston University under the direction of Professor Donald W. Sutherland. From 1992 to 1995, he was a research associate at the University of California, Los Angeles. From 1995 to 2000, he was a research associate at the University of Wyoming. From 2000 to 2002, he was a research associate at the University of Utah. From 2002 to 2003, he was a research associate at the University of Arkansas. From 2003 to 2006, he was a research associate at the University of Utah. From 2006 to present, he is a research associate at the University of Utah.From 1990 to 1995, Habib Torfi was a research chemist at Boston University. From 1995 to 2000, he was a research associate at the University of California, Los Angeles (UCLA). From 2000 to 2002, he was a research associate at the University of Wyoming. From 2002 to 2003, he was a research associate at the University of Arkansas. From 2003 to 2006, he was a research associate at the University of Utah. From 2006 to present, he is a research associate at the University of Utah.As a research chemist, Habib Torfi worked on a variety of chemical syntheses and inhibitors of bacterial proteinases. His work focused on the development of novel inhibitors of the proteinases betaine-1 and betaine-2, as well as theinhibitors betaine-19 and betaine-21. His work in this area gave him significant experience in the development and fielding of new products of biotechnology.Habib Torfi has also authored and published several papers in journals of biochemistry and molecular biology. These papers focus on the study of proteins and their regulatory phenomena. His most recent paper, "A water soluble protease inhibitor from the Ascomycota: structural analysis and crystal structure of a novel protease", was published in the journal Protein Science.